title: Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
abstract: BACKGROUND
  Biliary tract cancers are rare, and surgical resection is the standard treatment at early stages. However, reports on the benefits of adjuvant treatment following surgical resection are conflicting. This study aimed to evaluate the factors affecting survival and adjuvant treatments in patients with surgically treated biliary tract cancers.
  
  
  METHODS
  Patient clinical features, adjuvant treatments, and efficacy and prognostic factor data were evaluated. Survival analyses were performed using SPSS 15.0.
  
  
  RESULTS
  The median overall survival was 30.7 months (95% confidence interval [CI], 18.4-42.9 months). Median survival was 19 months (95% CI, 6-33) for patients treated with fluorouracil based chemotherapy and 53 months (95% CI, 33.2-78.8) with gemcitabine based chemotherapy (p=0.033). On univariate analysis, poor prognostic factors for survival were galbladder localization, perineural invasion, hepatic invasion, a lack of adjuvant chemoradiotherapy treatment, and a lack of lymph node dissection. On multivariate analysis, perineural invasion was a poor prognostic factor (p=0.008).
  
  
  CONCLUSIONS
  Biliary tract cancers generally have poor prognoses. The main factors affecting survival are tumour localization, perineural invasion, hepatic invasion, adjuvant chemoradiotherapy, and lymph node dissection. Gemcitabine-based adjuvant chemotherapy is more effective than 5-fluorouracil-based chemotherapy.
authors.affiliation: Department of Medical Oncology, Ataturk University Faculty of Medicine, Erzurum, Turkey E-mail : drolcun@hotmail.com.
authors.forename: Olcun Umit
authors.initials: OU
authors.lastname: Unal
authors.forename: Ilhan
authors.initials: I
authors.lastname: Oztop
authors.forename: Tugba
authors.initials: T
authors.lastname: Kos
authors.lastname: Assoc
authors.forename: Nedim
authors.initials: N
authors.lastname: Turan
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kucukoner
authors.forename: Kaan
authors.initials: K
authors.lastname: Helvaci
authors.forename: Veli
authors.initials: V
authors.lastname: Berk
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinc
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yildiz
authors.forename: Havva yesil
authors.initials: Hy
authors.lastname: Cinkir
authors.forename: Onder
authors.initials: O
authors.lastname: Tonyali
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Bilge
authors.initials: B
authors.lastname: Aktas
authors.forename: Ozan
authors.initials: O
authors.lastname: Balakan
authors.forename: Ahmet Ugur
authors.initials: AU
authors.lastname: Yilmaz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D005472:Fluorouracil; D000093542:Gemcitabine